Messenger RNA (mRNA) Technology has swiftly made its way to the field of vaccinology, offering a novel approach to immunization that differs fundamentally from traditional mechanisms of vaccination.
Brooklyn today announced it has completed a $20M financing to progress the development of the mRNA gene editing and cell therapies technology recently licensed from Factor Biosciences and Novellus Therapeutics.